RxDoctor Payments Data

Sarah McDowell, APRN

Primary Care · Celina, OHNPI 1225536881

Payments from drug & device makers

$867in general payments, 2019–2025

Across 31 payments — averaging $27.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$368
  • Novo Nordisk$170
  • Lilly USA, LLC$124
  • AstraZeneca$92
  • Pfizer$16
  • GSK$16
  • plus $82 from 6 others

What the payments were for

  • Food & beverage$867100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$867 in reported general payments places this provider in the 65th percentile of 321 primary care providers in Ohio.

See all primary care providers in Ohio

Medicare billing

Part B allowed, 2024
$14,688
Medicare patients
86
Services billed
964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide13$29,305
FarxigaDapagliflozin Propanediol24$18,590
JardianceEmpagliflozin11$11,488
Incruse ElliptaUmeclidinium Bromide15$4,483
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$1,277
Atorvastatin Calcium154$1,013
Fenofibrate11$808
Rosuvastatin Calcium54$760
SynthroidLevothyroxine Sodium22$490
Omeprazole46$485
Levothyroxine Sodium75$452
Tamsulosin Hcl21$441
Pantoprazole Sodium34$440
Bumetanide15$431
Amlodipine Besylate62$404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$124$29,30513 claims
AstraZenecaFarxiga$92$18,59024 claims
Boehringer IngelheimJardiance$12$11,48811 claims
GSKIncruse Ellipta$16$4,48315 claims
AbbVieSynthroid$368$49022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 321 primary care providers in Ohio.

Other primary care in Celina

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →